GlassScriptPhysician profile
Amy Whitlow
NPI 1376004853
$4,544.14
in general payments reported to CMS, 2019-2025
36 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $446 · 2023: $1,553 · 2024: $1,231 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,084 · Entertainment: $14.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.28 |
| Entertainment | $14.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $778.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $699.71 | 2022-2025 | |
| Lilly USA, LLC | $428.98 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $395.35 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $345.57 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $264.12 | 2022-2025 | Evenity, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $249.51 | 2022-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.85 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $108.44 | 2022-2025 | |
| Glaxosmithkline, LLC. | $105.39 | 2023-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.49 | 2023-2025 | Xifaxan |
| Dexcom, INC. | $92.69 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $66.64 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Insmed, INC. | $58.91 | 2025 | Arikayce |
| Idorsia Pharmaceuticals US INC | $54.82 | 2022-2023 | Quviviq |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Whitlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.